Continuous Glucose Monitoring (CGM) Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study
Authors' conclusion
CGM could aid in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes.
Study context
- Population
- Relatives of T1D probands, TrialNet Pathway to Prevention study; median age 16.8 years, 89% non-Hispanic White, 43.8% female; 7-day CGM and oral glucose tolerance tests (OGTTs) at 6-month intervals
- Participants
- 105 relatives
- Exposure
- Stage 2 vs stage 1 T1D vs autoantibody-negative relatives
- Stage 2n = 42
- Stage 1n = 53
- Autoantibody negativen = 10reference
- Outcome
- Association of CGM metrics with progression to clinical stage 3 T1D
Methodological detailsTrialNet Pathway to Prevention study, baseline data
- TrialNet Pathway to Prevention study
- Baseline data
Main finding
As reported in the abstract
CGM metrics associated with progression to stage 3 T1D
- ≥5% time with glucose ≥140 mg/dL associated with progression to stage 3
- P = 0.01
- ≥8% time with glucose ≥140 mg/dL associated with progression to stage 3
- P = 0.02
- ≥5% time with glucose ≥160 mg/dL associated with progression to stage 3
- P = 0.0001
- ≥8% time with glucose ≥160 mg/dL associated with progression to stage 3
- P = 0.02
Observational data: associations, not effects.
Further findings
Daytime glucose, time above thresholds and variability
- Stage 2 participants and those who progressed to stage 3 had higher mean daytime glucose, more time with glucose over 120, 140 and 160 mg/dL, and greater variability
Original publication
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →